Mayeul Ottaviani

Associate

Admitted to the Paris Bar in 2024, Mayeul Ottaviani joined August Debouzy the same year.

Specializing primarily in patent law, he provides both advisory and litigation support to French and international clients, defending their interests before national courts and offices and the Unified Patent Court (UPC). He also maintains a strong interest in FRAND matters and broader intellectual property issues.

Mayeul graduated from the University of Montpellier and gained significant experience working with other leading international law firms.

Practice Area

Patent Law

MEMBERSHIPS

LES France

EDUCATION

Master’s degree (Master 2) - Intellectual Property and Digital Law, University of Montpellier

LANGUAGES

French | English

AD Article

No commitment, no certificate: loose combinations and the SPC regulation

Read the full article on https://www.iam-media.com/article/no-commitment-no-certificate-loose-combinations-and-the-spc-regulation In this article, Franç
AD Article

UPC Court of Appeal Clarifies Standards for Imminent Infringement in Pharmaceutical Patent Disputes

The UPC Court of Appeal clarifies imminent infringement in pharma cases, overturning Boehringer v. Zentiva ruling and aligning with EU case law.
AD Article

The LD Lisbon Offers Some Limited Insight on Imminent Threat of Infringement

On 8 May 2025, the Lisbon Local Division of the Unified Patent Court (“UPC”) issued an order (Boehringer Ingelheim International GmbH v. Zentiva Portugal LDA, Lisbon LD, 8 May 2025, UPC_CFI_41/2025) denying a preliminary injunction application filed by Boehringer Ingelheim International GmbH (“Boehringer”) against Zentiva Portugal LDA (“Zentiva”).
AD Article

First Unified Patent Court Ruling on Second Medical Use Claims

On 13 May 2025, the Düsseldorf Local Division of the Unified Patent Court issued a landmark decision on the merits relating to a second medical use claim (Sanofi Biotechnology SAS and Regeneron Pharmaceuticals Inc. v. Amgen Inc. et al., 13 May 2025, UPC_CFI_505/2024). The decision follows an infringement action brought by Regeneron and Sanofi, respectively the proprietor and exclusive licensee of European Patent No 3 536 712 ("EP’712"), against various entities of the Amgen group, which subsequently filed a counterclaim for revocation. The claimants argued that the defendants’ product, evolocumab, marketed as Repatha® infringed EP’712.
More
Publications